KRX extends Gene One Life Science listing review committee deadline to Oct. 30, trade suspension continues
Bitget2026/09/28 08:57- KRX extended the deadline to convene a listing review committee for Gene One Life Science to Oct. 30, 2026.
- The review follows a substantive listing-eligibility examination triggered by a July 16, 2026 disclosure of a major management matter.
- Trading in the company’s shares will remain suspended until a decision on continued listing eligibility is reached.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
